Pfizer has announced a $400 million investment to expand active pharmaceutical ingredient (API) manufacturing at its Tuas facility in Singapore, reinforcing the company's Asia-Pacific supply chain resilience strategy.
The expansion will add 40,000 square meters of manufacturing space and is expected to create over 500 skilled positions. Production is scheduled to begin in Q3 2026.
Deja tu valoración